Justin Boggs is a writer for the E.W. Scripps company. Justin covers anything from politics to sports and entertainment.
Drugmaker AstraZenecasaid it intends to cap out-of-pocket prices of four medicines used to treat asthma and chronic obstructive pulmonary disease to $35 per month for many patients.
AstraZeneca added that the new price caps apply to those who are underinsured or don't have health insurance. Currently, the list price of Airsupra is $475 for a 120-dose inhaler. The company said those with private insurance typically pay $52 per month.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
AstraZeneca will cap inhaler costs at $35 per monthThe cost-reduction strategy follows a similar move from Boehringer Ingelheim, a rival in the medical device sector.
Read more »
Widely Used Inhalers Won't Cost More Than $35 a Month, AstraZeneca SaysWill other inhaler manufacturers like GlaxoSmithKline and Teva follow suit?
Read more »
The 20 Best Beauty Products Under $35 at Amazon: Shop Laneige, Tatcha, COSRX, Kosas and MoreShop our top picks under $35 from Amazon's extensive beauty product collection.
Read more »
The Amazon Echo Buds are down to a record-low $35 right nowWill Shanklin has been writing about gadgets, tech and their impact on humanity since 2011. Before joining Engadget, he spent five years creating and leading the mobile technology section for New Atlas. His work has also appeared on SlashGear, TechRadar, Digital Trends, AppleInsider, Android Central, HuffPost and others.
Read more »
Capital One set to acquire Discover in $35 billion stock dealBusiness Insider tells the global tech, finance, markets, media, healthcare, and strategy stories you want to know.
Read more »
Capital One says it's buying Discover for $35 billion, creating credit card and payments giantCapital One's $35 billion purchase of Discover would create a credit card and payments giant but is expected to draw heavy scrutiny from regulators and concern among consumer groups.
Read more »